From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Department of Chemistry, TRIGA, Johannes Gutenberg University, Mainz, Germany.
Clin Nucl Med. 2022 Jun 1;47(6):e444-e445. doi: 10.1097/RLU.0000000000004164. Epub 2022 Apr 4.
A 56-year-old man was diagnosed with calcitonin negative, plasma chromogranin A-positive, immunohistochemistry-negative, high-grade MTC (medullary thyroid cancer) behaving clinically like anaplastic thyroid cancer and presented with progressive disease after conventional therapies. A theranostic approach of 68Ga-DOTA.SA.FAPi-guided 177Lu-DOTAGA.(SA.FAPi)2 radionuclide therapy was administered on compassionate grounds as per the Declaration of Helsinki because known standard lines of treatment were ineffective. Treatment with a single cycle of 1.65 GBq 177Lu-DOTAGA.(SA.FAPi)2 demonstrated a sustainable reduction in the neck mass with significant improvement in the quality of life of the patient. 177Lu-DOTAGA.(SA.FAPi)2 is a potential theranostic option for high-grade MTC refractory to standard therapeutic options.
一位 56 岁男性被诊断为降钙素阴性、血浆嗜铬粒蛋白 A 阳性、免疫组织化学阴性、高级别 MTC（甲状腺髓样癌），临床表现类似于间变性甲状腺癌，在常规治疗后出现进行性疾病。根据赫尔辛基宣言，出于同情原因，采用了 68Ga-DOTA.SA.FAPi 引导的 177Lu-DOTAGA.(SA.FAPi)2 放射性核素治疗作为治疗方法，因为已知的标准治疗方法无效。患者接受了一个周期的 1.65GBq 177Lu-DOTAGA.(SA.FAPi)2 治疗，颈部肿块持续减少，生活质量显著改善。177Lu-DOTAGA.(SA.FAPi)2 是一种潜在的治疗选择，可用于对标准治疗方法耐药的高级别 MTC。
